The Allogeneic Future with Poseida's Kristin Yarema, Ph.D.

Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if their early autologous success can possibly live up to the promise of offering widespread accessibility to life-saving treatments. Dr. Yarema is the newly-appointed CEO at Poseida Therapeutics, a company we first covered with founding CEO Eric Ostertag, Ph.D. On this episode of the Business of Biotech, we'll learn about Dr. Yarema, how she earned the company's reins, how Poseida is positioning itself to crack the allogeneic CAR T code, and how strategic collaborations with the likes of Astellas and Roche are fueling the effort. --- #businessofbiotech #biopharma #biotech Subscribe to the podcast: Apple - podcasts.apple.com/us/podcast/business-of-biotech/… Spotify - open.spotify.com/show/5NhjpDeHzVlXPVqT9ezKwA YouTube -    • The Business Of Biotech Podcast  

• #science_technology
• #business_of_biotech
• #bioprocess_online
• #biotech
• #biopharma